Higher efficacy of pegylated interferon ‐α2b add‐on therapy in hepatitis B envelope antigen‐positive chronic hepatitis B patients on tenofovir monotherapy

ConclusionsTwenty‐four weeks of Peg‐IFNα2b as an add‐on sequential regimen to tenofovir is safe and resulted in greater loss of HBeAg and HBsAg compared to tenofovir monotherapy in selected HBeAg‐positive patients. Viral load reduction followed by immune modulation is a potentially useful approach.

Source: Hepatology Research - March 12, 2018 Category: Internal Medicine Authors: Ankur Jindal, Ashish Kumar Vyas, Devesh Kumar, Guresh Kumar, Manoj Kumar Sharma, Shiv Kumar Sarin Tags: Original Article Source Type: research